Comparative study of the usefulness of a novel insulin therapy in Japanese patients with Type 2 diabetes for concomitant use of an oral antidiabetic agent with twice-daily dosing either of insulin aspart, biphasic insulin aspart-30, or insulin detemir: Two times Insulin injection Combined with oral therapy Efficacy Study (TWICE study)
| Autor: | Mitsuyasu Itoh, Atsushi Suzuki, Taiya Katoh, Yoshikuni Sawai, Shogo Asano, Shigeo Imamura, Yoshinari Hayashi, Shinobu Goto, Nobuo Takahashi, Tetsuya Kawabe |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Fujita Medical Journal, Vol 7, Iss 1, Pp 1-7 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2189-7247 2189-7255 |
| DOI: | 10.20407/fmj.2019-023 |
| Popis: | Objectives: It is common to treat type 2 diabetes by regular injections of insulin. We compared the efficacy and safety of twice-daily administration of short-acting, premixed, and long-acting insulins. Methods: This was a multi-center, randomized, open-label, 52-week study. Patients were randomized to administer twice daily short-acting analog insulin (Aspart) plus a sulfonylurea (SU), premixed 70/30 analog insulin (Mix), or long-acting insulin (Detemir) plus a glinide derivative. Results: Twelve (mean baseline HbA1c 9.86±1.71%), eight (9.24±1.14%), and eight (11.26±1.81%) patients were treated with Aspart, Mix, or Detemir, respectively, for 52 weeks. After 12 weeks, the reductions in HbA1c were similar in the groups. A further significant reduction in HbA1c occurred between weeks 12 and 52 in the Detemir, but not the Aspart or Mix groups. After 52 weeks, the target of an HbA1c |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|